T2 Biosystems (TTOO) and Its Competitors Head to Head Review
T2 Biosystems (NASDAQ: TTOO) is one of 84 publicly-traded companies in the “Medical Equipment, Supplies & Distribution” industry, but how does it weigh in compared to its competitors? We will compare T2 Biosystems to related companies based on the strength of its risk, institutional ownership, dividends, valuation, profitability, analyst recommendations and earnings.
Valuation and Earnings
This table compares T2 Biosystems and its competitors top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|T2 Biosystems||$3.89 million||-$49.26 million||-2.31|
|T2 Biosystems Competitors||$827.05 million||$159.46 million||33.79|
T2 Biosystems’ competitors have higher revenue and earnings than T2 Biosystems. T2 Biosystems is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.
Institutional & Insider Ownership
60.6% of T2 Biosystems shares are owned by institutional investors. Comparatively, 63.4% of shares of all “Medical Equipment, Supplies & Distribution” companies are owned by institutional investors. 38.7% of T2 Biosystems shares are owned by company insiders. Comparatively, 13.0% of shares of all “Medical Equipment, Supplies & Distribution” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
This table compares T2 Biosystems and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|T2 Biosystems Competitors||-128.72%||-37.35%||-10.53%|
This is a summary of recent ratings for T2 Biosystems and its competitors, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|T2 Biosystems Competitors||322||1477||2588||105||2.55|
T2 Biosystems currently has a consensus target price of $6.83, indicating a potential upside of 51.18%. As a group, “Medical Equipment, Supplies & Distribution” companies have a potential upside of 5.65%. Given T2 Biosystems’ higher probable upside, equities analysts plainly believe T2 Biosystems is more favorable than its competitors.
Volatility & Risk
T2 Biosystems has a beta of 1.44, indicating that its share price is 44% more volatile than the S&P 500. Comparatively, T2 Biosystems’ competitors have a beta of 1.08, indicating that their average share price is 8% more volatile than the S&P 500.
T2 Biosystems competitors beat T2 Biosystems on 9 of the 12 factors compared.
About T2 Biosystems
T2 Biosystems, Inc. is an in vitro diagnostics company engaged in developing a technology platform offering an alternative to diagnostic methodologies. The Company’s T2 Magnetic Resonance platform (T2MR) enables detection of pathogens, biomarkers and other abnormalities in a range of unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum and urine, and can detect cellular targets at limits of detection as one colony forming unit per milliliter (CFU/mL). The Company’s initial development efforts target sepsis, hemostasis and Lyme disease. T2MR is a miniaturized, magnetic resonance-based approach that measures how water molecules react in the presence of magnetic fields. Its platform detects a range of targets, including molecular targets, such as deoxyribonucleic acid (DNA), immunodiagnostics, such as proteins, and a range of hemostasis measurements. The Company offers T2Dx Instrument (T2Dx) and the T2Candida Panel.
Receive News & Ratings for T2 Biosystems Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for T2 Biosystems Inc. and related companies with MarketBeat.com's FREE daily email newsletter.